KR20230117575A - Fcrn 항체 및 이의 사용 방법 - Google Patents

Fcrn 항체 및 이의 사용 방법 Download PDF

Info

Publication number
KR20230117575A
KR20230117575A KR1020237018942A KR20237018942A KR20230117575A KR 20230117575 A KR20230117575 A KR 20230117575A KR 1020237018942 A KR1020237018942 A KR 1020237018942A KR 20237018942 A KR20237018942 A KR 20237018942A KR 20230117575 A KR20230117575 A KR 20230117575A
Authority
KR
South Korea
Prior art keywords
antibody
administration
seq
baseline
fcrn
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237018942A
Other languages
English (en)
Korean (ko)
Inventor
신두 람칸드렌
홍 순
윌리엄 대니
산티아코 아로요
레오나 이. 링
조셀린 에이치. 레우
지안후아 진
마리-헬레네 주빈
키스 카처
숀 블랙
야오웨이 쥬
Original Assignee
모멘타 파머슈티컬스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 모멘타 파머슈티컬스 인코포레이티드 filed Critical 모멘타 파머슈티컬스 인코포레이티드
Publication of KR20230117575A publication Critical patent/KR20230117575A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
KR1020237018942A 2020-11-06 2021-11-05 Fcrn 항체 및 이의 사용 방법 Pending KR20230117575A (ko)

Applications Claiming Priority (19)

Application Number Priority Date Filing Date Title
US202063110884P 2020-11-06 2020-11-06
US63/110,884 2020-11-06
US202163137972P 2021-01-15 2021-01-15
US63/137,972 2021-01-15
US202163173126P 2021-04-09 2021-04-09
US63/173,126 2021-04-09
US202163173919P 2021-04-12 2021-04-12
US63/173,919 2021-04-12
US202163174423P 2021-04-13 2021-04-13
US63/174,423 2021-04-13
US202163175440P 2021-04-15 2021-04-15
US63/175,440 2021-04-15
US202163203075P 2021-07-07 2021-07-07
US202163219155P 2021-07-07 2021-07-07
US202163203077P 2021-07-07 2021-07-07
US63/203,077 2021-07-07
US63/203,075 2021-07-07
US63/219,155 2021-07-07
PCT/US2021/058188 WO2022098955A1 (en) 2020-11-06 2021-11-05 Fcrn antibodies and methods of use thereof

Publications (1)

Publication Number Publication Date
KR20230117575A true KR20230117575A (ko) 2023-08-08

Family

ID=81455198

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237018942A Pending KR20230117575A (ko) 2020-11-06 2021-11-05 Fcrn 항체 및 이의 사용 방법

Country Status (12)

Country Link
US (1) US20220144946A1 (https=)
EP (1) EP4240417A4 (https=)
JP (1) JP2023548858A (https=)
KR (1) KR20230117575A (https=)
AU (1) AU2021376364A1 (https=)
CA (1) CA3200972A1 (https=)
IL (1) IL302516A (https=)
JO (1) JOP20230098A1 (https=)
MX (1) MX2023005313A (https=)
PH (1) PH12023551241A1 (https=)
TW (1) TW202233236A (https=)
WO (1) WO2022098955A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12240875B2 (en) 2017-12-08 2025-03-04 argenx BV Use of FCRN antagonists for treatment of generalized myasthenia gravis
KR102904658B1 (ko) 2017-12-13 2025-12-29 모멘타 파머슈티컬스 인코포레이티드 FcRn 항체 및 이의 사용 방법
CA3101462A1 (en) 2018-06-08 2019-12-12 Argenx Bvba Compositions and methods for treating immune thrombocytopenia
KR102921210B1 (ko) 2018-07-20 2026-01-30 모멘타 파머슈티컬스 인코포레이티드 Fcrn 항체 조성물
BR112022013554A2 (pt) 2020-01-08 2022-09-06 argenx BV Métodos para tratar distúrbios do pênfigo
CA3258000A1 (en) 2022-06-15 2023-12-21 argenx BV FCRN/ANTIGEN BINDING MOLECULES AND METHODS OF USE
EP4615481A1 (en) * 2022-11-07 2025-09-17 argenx BV Methods for treating lupus nephritis using fcrn antagonists
WO2024163894A1 (en) * 2023-02-04 2024-08-08 Momenta Pharmaceuticals, Inc. Compositions and methods for treating hemolytic disease of the fetus and newborn
TW202527982A (zh) * 2023-09-11 2025-07-16 美商默門塔醫藥公司 Fcrn抗體之醫藥組成物
WO2025163617A1 (en) * 2024-02-04 2025-08-07 Momenta Pharmaceuticals, Inc. Compositions and methods for treating sjögren's disease
WO2025186787A1 (en) * 2024-03-08 2025-09-12 Momenta Pharmaceuticals, Inc. Compositions and methods for treating fetal and neonatal alloimmune thrombocytopenia

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250052465A (ko) * 2015-01-30 2025-04-18 모멘타 파머슈티컬스 인코포레이티드 ＦｃＲｎ 항체 및 이의 사용 방법
CA3038894A1 (en) * 2016-09-28 2018-04-05 Board Of Regents, The University Of Texas System Antibody and protein therapeutic formulations and uses thereof
US12240875B2 (en) * 2017-12-08 2025-03-04 argenx BV Use of FCRN antagonists for treatment of generalized myasthenia gravis
KR102904658B1 (ko) * 2017-12-13 2025-12-29 모멘타 파머슈티컬스 인코포레이티드 FcRn 항체 및 이의 사용 방법
MX2021000790A (es) * 2018-07-20 2021-07-21 Momenta Pharmaceuticals Inc Composiciones de anticuerpos del receptor neonatal para fc y metodos de uso de las mismas.
MA53903A (fr) * 2018-10-16 2021-08-25 UCB Biopharma SRL Méthode de traitement de la myasthénie grave
EP4007605A4 (en) * 2019-08-01 2023-08-16 Momenta Pharmaceuticals, Inc. ANTI-FCRN ANTIBODIES AND METHODS OF USE THEREOF

Also Published As

Publication number Publication date
CA3200972A1 (en) 2022-05-12
TW202233236A (zh) 2022-09-01
IL302516A (en) 2023-07-01
AU2021376364A9 (en) 2024-09-12
EP4240417A1 (en) 2023-09-13
MX2023005313A (es) 2023-07-11
JOP20230098A1 (ar) 2023-05-04
PH12023551241A1 (en) 2023-11-20
AU2021376364A1 (en) 2023-06-22
WO2022098955A1 (en) 2022-05-12
US20220144946A1 (en) 2022-05-12
EP4240417A4 (en) 2024-10-02
WO2022098955A9 (en) 2022-06-09
JP2023548858A (ja) 2023-11-21

Similar Documents

Publication Publication Date Title
KR20230117575A (ko) Fcrn 항체 및 이의 사용 방법
JP7420720B2 (ja) ＦｃＲｎ抗体およびその使用方法
US20220259308A1 (en) Fcrn antibodies and methods of use thereof
KR102505995B1 (ko) FcRn 항체 및 이의 사용 방법
CN112079922B (zh) 抗人p40蛋白域抗体及其用途
WO2024173877A1 (en) Anti-tl1a antibody compositions and methods of treatment in the liver
WO2024173865A2 (en) Anti-tl1a antibody compositions and methods of treatment in the kidney
WO2024173838A2 (en) Anti-tl1a antibody compositions and methods of treatment in the bile duct
US20240182598A1 (en) Compositions and methods for treating pediatric myasthenia gravis
EA051865B1 (ru) Антитела к fcrn и способы их применения
CN116782939A (zh) FcRn抗体及其使用方法
EA050428B1 (ru) АНТИТЕЛА ПРОТИВ FcRn И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
HK40072884A (en) Fcrn antibodies and methods of use thereof
CN117120092A (zh) 用于治疗儿科重症肌无力的组合物和方法
EA052034B1 (ru) Композиции и способы лечения детской миастении гравис

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20230605

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20241031

Comment text: Request for Examination of Application